| Ac-225-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study |
57 |
| Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F-18]FDG: version 1.0 |
48 |
| FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature |
47 |
| FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC |
47 |
| Metabolic activity by F-18-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC |
40 |
| Absolute number of new lesions on F-18-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab |
39 |
| First validation of myocardial flow reserve assessed by dynamic Tc-99m-sestamibi CZT-SPECT camera: head to head comparison with O-15-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study |
35 |
| Prediction of outcome using pretreatment F-18-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy |
34 |
| Third-line treatment and Lu-177-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review |
33 |
| Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline |
33 |
| PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival |
32 |
| Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis |
32 |
| Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery |
29 |
| European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma |
29 |
| Prospective observational study of Lu-177-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity |
29 |
| EANM procedure guidelines for radionuclide therapy with Lu-177-labelled PSMA-ligands (Lu-177-PSMA-RLT) |
29 |
| Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement) |
28 |
| The role of interim F-18-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma |
28 |
| Current status of theranostics in prostate cancer |
28 |
| F-18-NaF and F-18-FDG as molecular probes in the evaluation of atherosclerosis |
25 |
| External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy |
25 |
| Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer |
25 |
| Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions |
25 |
| Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives |
25 |
| Discovery and preclinical characterization of [F-18]PI- a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies |
24 |
| Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy |
23 |
| Recommendations on nuclear and multimodality imaging in IE and CIED infections |
23 |
| Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis |
23 |
| Prognostic value of baseline metabolic tumor volume measured on F-18-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy |
23 |
| Value of F-18-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients |
22 |
| EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond |
22 |
| Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics |
22 |
| Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics |
22 |
| Predicting locally advanced rectal cancer response to neoadjuvant therapy with F-18-FDG PET and MRI radiomics features |
21 |
| Zr-89-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer |
20 |
| PRRT genomic signature in blood for prediction of Lu-177-octreotate efficacy |
20 |
| Prospective comparison of Ga-68-PSMA PET/CT, F-18-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer |
20 |
| Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI |
20 |
| EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations |
19 |
| Ga-68-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng/ml. Efficacy and impact on treatment strategy |
19 |
| Ga-68-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy |
19 |
| Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma |
19 |
| Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group |
19 |
| The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes |
19 |
| Diagnostic performance of F-18-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer |
19 |
| Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study |
19 |
| Preliminary results on response assessment using Ga-68-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy |
19 |
| Salvage peptide receptor radionuclide therapy with [Lu-177-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours |
18 |
| Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis |
18 |
| Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study |
18 |
